Sprint Bioscience Ab Stock Target Price
| SPRINT Stock | SEK 1.67 0.04 2.45% |
Sprint Bioscience AB fundamentals help investors to digest information that contributes to Sprint Bioscience's financial success or failures. It also enables traders to predict the movement of Sprint Stock. The fundamental analysis module provides a way to measure Sprint Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sprint Bioscience stock.
Sprint |
Sprint Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sprint Bioscience's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sprint Bioscience could also be used in its relative valuation, which is a method of valuing Sprint Bioscience by comparing valuation metrics of similar companies.Sprint Bioscience is currently under evaluation in target price category among its peers.
Sprint Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Shares Owned By Insiders | 35.31 % | |||
| Shares Owned By Institutions | 2.59 % | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 35.11 M | |||
| Gross Profit | 24.59 M | |||
| EBITDA | (24.22 M) | |||
| Net Income | (25.08 M) | |||
| Cash And Equivalents | 13.82 M | |||
| Cash Per Share | 1.19 X | |||
| Debt To Equity | 32.20 % | |||
| Current Ratio | 2.69 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (40.12 M) | |||
| Earnings Per Share | (0.75) X | |||
| Target Price | 32.0 | |||
| Number Of Employees | 34 | |||
| Beta | 1.32 | |||
| Market Capitalization | 53.17 M | |||
| Total Asset | 79.14 M | |||
| Retained Earnings | (39 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 25 M | |||
| Current Liabilities | 21 M | |||
| Net Asset | 79.14 M |
About Sprint Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sprint Bioscience AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sprint Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sprint Bioscience AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.